We will be announcing publications internally each month.

John Wayne Cancer Institute 2020 Publications

Feb 2020 – March 2020


  • The department of Translational Neurosciences & Neurotherapeutics presents a new study in BioTechniques: cellular thermal shift analysis for interrogation of CRISPR-assisted proteomic changes. Read the publication, Cellular thermal shift analysis for interrogation of CRISPR-assisted proteomic changes to learn the results. https://www.future-science.com/doi/10.2144/btn-2019-0100



  • The department of Translational Molecular Oncology published a new breast cancer study in Nature Communications. The results suggest that 3D epigenome remodeling is a key mechanism underlying endocrine resistance in ER+ breast cancer. Read the publication, Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer to learn more. https://www.nature.com/articles/s41467-019-14098-x


  • The Center for Endocrine Tumors and disorders published a new article highlighting the updates in parathyroid disease and advances in parathyroid surgery. Read the publication, Recent advances in the understanding and management of primary hyperparathyroidism to learn about the management of primary hyperparathyroidism. https://f1000research.com/articles/9-143


April 2020


  • Steven J. O’Day, M.D., and his colleagues at the Society Immunotherapy of Cancer: Fernanda I. Arnaldez, Charles G. Drake, Bernard A. Fox, Binqinq Fu, Walter J. Urba, Vincenzo Montesarchio, Jeffrey S. Weber, Haiming Wei, Jon M. Wigginton, and Paolo A. Ascierto, have published a new study in the Journal for ImmunoTherapy of Cancer, entitled: The Society for Immunotherapy of Cancer Perspective on Regulation of Interleukin 6 Signaling in COVID-19 –related Systemic Inflammatory Response. This publication examines how an immunology-informed approach may help identify alternative agents to modulate the pathological inflammation seen in COVID-19 patients. Learn how the cancer immunotherapy community is poised to contribute to the current fight against COVID-19 by reading the attached publication. 


  • The Drug Discovery and Nanomedicine Laboratory (Yenugonda V and Waters A), along with Kesari S, and Allnutt AB, presents a review article in ACS Chemical Neuroscience highlighting the importance of Cdk5 activity and function in the brain and demonstrates how deregulation of Cdk5 can contribute to the development of neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease. Read the publication, Physiological and pathological roles of Cdk5: potential directions for therapeutic targeting in neurodegenerative disease, to learn more: https://www.ncbi.nlm.nih.gov/pubmed/32286796.
    This article was also selected for ACS Editors’ Choice!


May 2020


  • Przemyslaw W. Twardowski, M.D., and his colleagues: Johann de Bono, M.B., Ch.B., Ph.D., Joaquin Mateo, M.D., Ph.D., Karim Fizazi, M.D., Ph.D., Fred Saad, M.D., Neal Shore, M.D., Shahneen Sandhu, M.D., Kim N. Chi, M.D., Oliver Sartor, M.D., Neeraj Agarwal, M.D., David Olmos, M.D., Ph.D., Antoine Thiery-Vuillemin, M.D., Ph.D., et al, have published a new study in the New England Journal of Medicine, entitled: Olaparib for Metastatic Castration-Resistant Prostate Cancer. This publication demonstrates the benefits of olaparib (PARP inhibitor) in patients with selected mutations of DNA repair system, a major significance for the treatment of prostate cancer. The results of this study are expected to provide a new, valuable treatment option for about 25% of patients with advanced prostate cancer who harbor DNA repair mutations. Learn more: https://www.nejm.org/doi/full/10.1056/NEJMoa1911440?query=featured_home


  • The Department of Translational Molecular Medicine: Wang X, Bustos M, Zhang X, Ramos R, Tan C, Iila Y, Chang S, Salomon M, Tran K, Gentry R, Kravtsova-Ivantsiv Y, Kelly D, Mills G, Ciechanover A, Mao Y,Hoon D., in collaboration with A. Chiechanover (Nobel Laureate) Israel, D Kelly PNI, and Y. Mao Director U.of Fudan Neurosurgery and Clinical Programs Shanghai, published a new study in Cancers entitled:Downregulation of the Ubiquitin-E3 Ligase RNF123 Promotes Upregulation of the NF-κB1 Target SerpinE1 in Aggressive Glioblastoma Tumors. This study examined the role of the ubiquitin E3-ligase RNF123 in modulating downstream NF-κB1 targets in glioblastoma (GB) tumor progression. Learn more:https://www.ncbi.nlm.nih.gov/pubmed/32349217


  • Romela Irene Ramos, MSc, laboratory manager of the Department of Translational Molecular Medicine, along with: Bustos M, Wu J, Jones P, Chang S, Kiyohara E, Tran K, Zhang X, Izraely S, Sagi-Assif O, Witz I, Davies M, Mills G, Kelly D, Irie R, Hoon D., in collaboration with MD Anderson, D. Kelly PNI, and Oregon Health Science U., have published a new study in Molecular Oncology entitled: Upregulation of Cell Surface GD3 Ganglioside Phenotype is Associated with Human Melanoma Brain Metastasis. This study demonstrates cell surface ganglioside GD3 phenotype associates with melanoma brain tumor progression and treatment responses to Icaritin. Learn more:https://www.ncbi.nlm.nih.gov/pubmed/32358995


  • Janie Grumley, M.D., FACS, and her colleagues: Crown A, Laskin R, Weed C, Rocha FG, have published a new study in Annals of Surgical Oncology entitled: Evaluating Need for Additional Imaging and Biopsy After Oncoplastic Breast-Conserving Surgery. This study examines breast imaging after oncoplastic breast conserving surgery. Learn more: https://www.ncbi.nlm.nih.gov/pubmed/32372312


June 2020





  • Congratulations to the Department of Translational Molecular Medicine, Department of Genomic Sequencing Center, Department of Immuno-Oncology and Clinical Research and The Pacific Neuroscience Institute, on your publication in Cancers, entitled: Integrated Assessment of Circulating Cell-Free MicroRNA Signatures in Plasma of Patients with Melanoma Brain Metastasis. Matias A. Bustos, Kevin D. Tran, Negin Rahimzadeh, Rebecca Gross, Selena Y. Lin, Yoshiaki Shoji, Tomohiro Murakami, Christine L. Boley, Linh T. Tran, Hunter Cole, Daniel F. Kelly, Steven O’Day, and Dave S.B. Hoon. Cancers 2020, 12, 1692; doi:10.3390/cancers12061692







July & August 2020